[theold]

Dr Ella told CNBC-TV18 in an interview. Six experts News18.com spoke to agreed.

These experts include two officials from public sector units that have been given contracts to manufacture Covaxin, an official from one of the top private vaccine makers in India, a former chief of a major vaccine producer who is now a consultant, a scientist working mainly on vaccines and biological products apart from a source from Bharat Biotech. All of them spoke to News18.com on condition of anonymity.

According to experts, the number of steps to manufacture a vaccine with inactivated virus is much more than ones carried out for adenovirus vector-based vaccines. Covaxin falls in the former category and Covishield in the latter.

Whole inactivated virus vaccine produced in vero cells is a very complex manufacturing process, involving several steps with high degree of complexity,” he said.

https://sg.yahoo.com/news/why-bharat-bio...58161.html

[dynamite]

Means what? Sinovac should be more expensive than p and m?

[theold]

Means what? Sinovac should be more expensive than p and m?

Definitely.

[debono]

Means what? Sinovac should be more expensive than p and m?

Why is this so, it comes from China it should be cheaper...

[cityhantam]

Why is this so, it comes from China it should be cheaper...

If it comes from India, it should be even cheaper! 

[Tangsen]

Again india variant CECA with their bird talk ...... ask them go fugg their holy cow lah

[theold]

Bharat Biotech: More than just Covaxin

As the story goes, the couple who were settled in the US, with successful careers, decided one fine morning in 1996 to return to India and help in its development. Krishna surrendered his American passport, the couple sold their house and put that money into starting Bharat Biotech with a seed capital of $3.5 million.

He’s simple and warm, with no airs whatsoever for a person who founded and heads a company that has supplied about 10 billion doses of different vaccines to 123 countries in the world, and crucially, is at the forefront of India’s fight against the Covid-19 pandemic.

The company chose to take the difficult route of producing an inactivated virus vaccine.

It is not just complicated technology but also more expensive to produce and time-consuming. Yet, Ella chose this because of his conviction that inactivated virus vaccines are superior to mRNA or adeno virus vaccines.

“We wanted to focus on both humoral and cell mediated responses, against not just spike proteins but also the nucleocapsid proteins which have also been determined to be immunogenic. Nucleocapsid proteins are known to be more stable and develop less variants, as seen with spike proteins. Our long experience in developing other inactivated virus vaccines helped us. The adjuvant in Covaxin triggers T-cell responses,” says Ella.

Unlike mRNA vaccines that induce the body to produce the antigen of interest, inactivated virus vaccines give a readymade antigen to stimulate the immune response. Not just this, Bharat Biotech selected 6 micrograms as the dosage even though 3 micrograms worked as well during Phase I/II trials, because the company wanted to be abundantly cautious.


https://www.thehindubusinessline.com/spe...684598.ece